Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2/3 2Phase 3 1Phase 2 1

Status

Recruiting 4Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gynecologic 6

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 2Platinum-resistant Ovarian Cancer 1Ovarian Cancer Recurrent 1Adenoviridae Infections 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
1-dodecylpyridoxal × 90 days × Clear all
NCT07564141 2026-06-03

RAINFOLâ„¢-07

Genmab

Phase 3 Not yet recruiting
688 enrolled
Gynecologic

Ovarian Neoplasms

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
460 enrolled
Gynecologic

Ovarian Cancer Recurrent

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Daiichi Sankyo

Phase 2/3 Recruiting
860 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting
29 enrolled

Adenoviridae Infections

NCT05551507 2026-05-04

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Novita Pharmaceuticals, Inc.

Phase 2/3 Active not recruiting
380 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡